Amgen has now answered Coherus BioSciences’ complaint and denies that it has infringed on Coherus’ patents. Amgen also said that the patents are invalid for failure to comply with requirements of the law.
In a complaint filed earlier this year, biosimilar developer Coherus BioSciences alleged that Amgen, maker of the EU-authorized and marketed Amgevita, a biosimilar adalimumab, has infringed on a number of Coherus’ patents directed to the stable formulation of adalimumab.
According to Coherus’ original complaint, manufacture of the EU-marketed Amgevita in the United States constitutes infringement on 3 of its US patents, and this infringement warrants an award of damages.
Later, Coherus amended its complaint to include alleged infringement of a fourth patent, also directed to the stable aqueous pharmaceutical composition of adalimumab.
Amgen has now answered Coherus’ complaint, and denies that it has infringed on Coherus’ patents. Amgen also said that the patents are invalid for failure to comply with requirements of the law.
According to Amgen, Coherus “had to deceive the United States Patent and Trademark Office” in order to procure patents that had claims to anticipated and obvious adalimumab formulations. The Amgevita-maker’s response states that the patents’ inventor and Coherus’ attorney together withheld material prior art and other information from the office, and says that these parties misstated material facts with the intention to deceive.
Amgen’s response goes on to say that the inventor and attorney filed multiple petitions for inter partes review (IPR) against claims of patents held by AbbVie (maker of the brand-name adalimumab, Humira), and that these petitions took positions that were directly contrary to those taken in their own applications for patents.
Amgen says these positions were material to the patentability of the claims at issue in Coherus’ complaint, and the existence of these IPR challenges, says Amgen, were not disclosed to the patent office. Disclosure of these issues, says Amgen, could have changed which claims of the asserted patents that the office would have allowed.
Coherus also withheld material prior art references, says Amgen, including the most pertinent prior art from AbbVie’s portfolio of adalimumab patents. However, other, less relevant patents in the same family were submitted. “The single most reasonable inference to be drawn,” says Amgen’s response, is that Coherus’ agents “acted with the intention of deceiving the Patent Office and procuring the Asserted Patents on the basis of an incomplete and/or misleading record.”
Amgen seeks a trial by jury, and has asked the court to deny all forms of relief to Coherus, dismiss Coherus’ complaint, declare that Amgen has not infringed the patents, and declare the patents invalid and unenforceable.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.